A citation-based method for searching scientific literature

Paul T C Wan, Mathew J Garnett, S Mark Roe, Sharlene Lee, Dan Niculescu-Duvaz, Valerie M Good, C Michael Jones, Christopher J Marshall, Caroline J Springer, David Barford, Richard Marais. Cell 2004
Times Cited: 2015



Zhan Yao, Yijun Gao, Wenjing Su, Rona Yaeger, Jessica Tao, Na Na, Ying Zhang, Chao Zhang, Andrey Rymar, Anthony Tao, Neilawattie M Timaul, Rory Mcgriskin, Nathaniel A Outmezguine, HuiYong Zhao, Qing Chang, Besnik Qeriqi, Mariano Barbacid, Elisa de Stanchina, David M Hyman, Gideon Bollag, Neal Rosen. Nat Med 2019
Times Cited: 89




List of shared articles



Times cited

Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy.
Shivshankari Rajkumar, Diana Berry, Kayla A Heney, Colton Strong, LeeAnn Ramsay, Mathieu Lajoie, Rached Alkallas, Tan-Trieu Nguyen, Cameron Thomson, Mozhdeh Ahanfeshar-Adams,[...]. Cell Rep 2022
4

BRAF/MEK inhibition in NSCLC: mechanisms of resistance and how to overcome it.
Ioannis Tsamis, Georgia Gomatou, Stavroula Porfyria Chachali, Ioannis Panagiotis Trontzas, Vasileios Patriarcheas, Emmanouil Panagiotou, Elias Kotteas. Clin Transl Oncol 2022
0

RAS pathway regulation in melanoma.
Amira Al Mahi, Julien Ablain. Dis Model Mech 2022
1


BRAF Mutations: The Discovery of Allele- and Lineage-Specific Differences.
Aphrothiti J Hanrahan, David B Solit. Cancer Res 2022
0

Prevalence of class I-III BRAF mutations among 114,662 cancer patients in a large genomic database.
Jeff Owsley, Matthew K Stein, Jason Porter, Gino K In, Mohamed Salem, Steven O'Day, Andrew Elliott, Kelsey Poorman, Geoffrey Gibney, Ari VanderWalde. Exp Biol Med (Maywood) 2021
8